SEARCH:   Advanced

Blood, 1 November 2004, Vol. 104, No. 9, pp. 2943-2946. Prepublished online as a Blood First Edition Paper on July 6, 2004; DOI 10.1182/blood-2004-05-1747. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-05-1747v1 104/9/2943    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bower, M. Articles by Stebbing, J. Search for Related Content PubMed PubMed Citation Articles by Bower, M. Articles by Stebbing, J. Related Collections Hematopoiesis and Stem Cells Neoplasia Phagocytes Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report Protease inhibitors potentiate chemotherapy-induced neutropenia Mark Bower, Neil McCall-Peat, Natalie Ryan, Liz Davies, Anne Marie Young, Srirupa Gupta, Mark Nelson, Brian Gazzard, and Justin Stebbing From The Chelsea and Westminster Hospital, London, United Kingdom. Pharmacokinetic interactions between chemotherapy and highly active antiretroviral therapy (HAART) are described, but there are few data on their clinical relevance. Patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) were treated with concomitant HAART and infusional cyclophosphamide-doxorubicin-etoposide (CDE) chemotherapy. We compared neutropenia according to whether patients received protease inhibitor (PI)-based HAART or non-PI regimens. Differences in survival, response rates, immunologic parameters, and virologic parameters were also investigated. The day-10 (Mann-Whitney U test; P = .012) and day-14 (P = .025) neutrophil counts were significantly lower in patients receiving PIs, though there were no differences in the number of days of granulocyte colony-stimulating factor (G-CSF) administered between groups (P = .16). Grade 3 or 4 infections requiring hospitalization were recorded for a total of 58 (31%) of 190 cycles of CDE: 23 (48%) of 48 when prescribed PIs and 35 (25%) of 142 with concomitant PI-sparing HAART (2 test; P = .0025). There were no statistically significant differences in the response rates, relapse-free survival, or disease-free survival between patients receiving PIs and those not receiving PIs. PI-based HAART appears to significantly potentiate the myelotoxicity of CDE chemotherapy. This potentiation may be a consequence of microsomal enzyme inhibition reducing the metabolism of cytotoxics in this regimen. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Gurney and R. Shaw Obesity in Dose Calculation: A Mouse or an Elephant? J. Clin. Oncol., October 20, 2007; 25(30): 4703 - 4704. [Full Text] [PDF] C. Palmieri, T. Treibel, O. Large, and M. Bower AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy QJM, December 1, 2006; 99(12): 811 - 826. [Abstract] [Full Text] [PDF] J Cadranel, D Garfield, A Lavole, M Wislez, B Milleron, and C Mayaud Lung cancer in HIV infected patients: facts, questions and challenges. Thorax, November 1, 2006; 61(11): 1000 - 1008. [Abstract] [Full Text] [PDF] M. Bower, D. Mazhar, and J. Stebbing Should Cervical Cancer Be an Acquired Immunodeficiency Syndrome-Defining Cancer? J. Clin. Oncol., June 1, 2006; 24(16): 2417 - 2419. [Full Text] [PDF] S. Combs, N. Neil, and D. M. Aboulafia Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. Oncologist, June 1, 2006; 11(6): 666 - 673. [Abstract] [Full Text] [PDF] N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF] D. Mazhar, J. Stebbing, R. Lewis, M. Nelson, B. G. Gazzard, and M. Bower The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe Blood, April 15, 2006; 107(8): 3412 - 3414. [Full Text] [PDF] L. D. Kaplan, J. Y. Lee, R. F. Ambinder, J. A. Sparano, E. Cesarman, A. Chadburn, A. M. Levine, and D. T. Scadden Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood, September 1, 2005; 106(5): 1538 - 1543. [Abstract] [Full Text] [PDF] M. Bower, B. Gazzard, S. Mandalia, T. Newsom-Davis, C. Thirlwell, T. Dhillon, A. M. Young, T. Powles, A. Gaya, M. Nelson, et al. A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy Ann Intern Med, August 16, 2005; 143(4): 265 - 273. [Abstract] [Full Text] [PDF] M. Cruciani, G. Gatti, E. Vaccher, G. Di Gennaro, R. Cinelli, M. Bassetti, U. Tirelli, and D. Bassetti Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients J. Antimicrob. Chemother., April 1, 2005; 55(4): 546 - 549. [Abstract] [Full Text] [PDF] M. Spina, U. Jaeger, J. A. Sparano, R. Talamini, C. Simonelli, M. Michieli, G. Rossi, E. Nigra, M. Berretta, C. Cattaneo, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials Blood, March 1, 2005; 105(5): 1891 - 1897. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020